Clinical Studies - Solid Tumor Vaccine Trials

See Pediatric Cancer Immunotherapy Program for information on the below study

A Phase I Trial Combining Decitabine and Vaccine Therapy for Patients with Neuroblastoma

Status: Active



There are limited treatment options for patients with neuroblastoma.  Recent studies have demonstrated that demethylating agents, such as decitabine (DAC) can increase the expression of several cancer antigens such as MAGE-A1, MAGE-A3, and NY-ESO-1 on tumor cells, including neuroblastoma. The purpose of this study is to combine DAC with a cancer antigen/dendritic cell vaccine in patients with relapsed stage IV neuroblastoma.We will determine whether patients develop immune responses to these cancer antigens and have changes in their tumor size as a result of this regimen.



Jenny Gullett (717) 531-5299



  • Pediatric Solid Tumors
  • Therapy Refractory Disease